ImmuPharma’s Tim McCarthy discusses the £8.4 million fundraise, the progress of the Lupuzor Phase III trial, key milestones and the June symposium with Professor Muller in this exclusive interview with DirectorsTalk
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the recent £8.4 million fundraiser and the participants, explains how the Lu-puzor trial is progressing, provides key milestones for the
Dr Mike Mitchell analyst at Panmure Gordon said this morning “This morning ImmuPharma has released prelims for the year-ending 31 December 2015. Today’s numbers reflect a business in development-phase –
On outlook Tim McCarthy, Chairman Immupharma PLC (LON:IMM), said: “ImmuPharma is focused on ensuring the successful development of the late stage clinical development of Lupuzor(TM) through its pivotal Phase III trial.
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wednesday 4 May 2016.
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor(TM), its
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, confirmed to DirectorsTalk that it has received a TR-1 by Aviva plc and its subsidiaries confirming its increased holding in ImmuPharma
1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlyingissuer of existing shares to which votingrights are attached: Immupharmaplc 2. Reason for the notification (please tick
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Immupharma plc 2. Reason for
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
